COMPANY INFO
Enlaza Therapeutics, founded in 2020, is a biotechnology research company headquartered in San Diego, California. The company was co-founded by Dr. Sergio Duron and Dr. Sanford (Sandy) Madigan and employs between 51-200 people. Enlaza Therapeutics pioneers the development of first-in-class covalent protein therapeutics using their proprietary War-Lock technology to create highly selective biologic drugs that irreversibly bind to disease targets, aiming to transform the treatment of cancer and other serious diseases. Their approach enhances efficacy and safety by enabling sustained target occupancy with minimal systemic exposure. The company's website is https://enlazatx.com.
Enlaza Therapeutics, founded in 2020, is an innovative biotechnology research company in the drug discovery sector, headquartered in La Jolla, California. The company, co-founded by Dr. Sergio Duron and Dr. Sanford (Sandy) Madigan, is focused on developing first-in-class covalent protein therapeutics using its proprietary War-Lock technology. Enlaza Therapeutics aims to transform the treatment of cancer and other serious diseases by creating selective biologic drugs that irreversibly bind to disease targets, thereby improving efficacy and safety with minimal systemic exposure. With a growing team dedicated to advancing protein therapeutics, Enlaza is making significant strides in the biotech industry.
Enlaza Therapeutics funding has been notable for its scale and execution, raising a total of $161 million over two significant funding rounds. The initial seed round provided crucial capital for launching the company and developing its protein therapeutics platform, followed by a substantial Series A investment to propel its proprietary technology and advance clinical programs. The company’s funding strategy emphasizes partnering with leading venture capital firms and strategic investors to drive innovation and support the clinical advancement of its therapeutic pipeline.
This Series A round was secured to accelerate the development of Enlaza’s proprietary covalent protein technologies and move pipeline programs closer to clinical trials. Funds are being used to support research, drug discovery, and operational expansion, enhancing the company’s position in next-generation biologic therapeutics.
The seed round provided foundational capital for Enlaza Therapeutics’ initial launch, staffing, and early-stage development of its protein therapeutics platform. This investment supported the build-out of its proprietary War-Lock technology and the establishment of preclinical proof-of-concept.
As the lead investor in Enlaza Therapeutics' Series A funding, J.P. Morgan Asset Management's Life Sciences group played a pivotal role in backing the advancement of Enlaza’s technology and clinical programs. Their expertise in healthcare investments brings strong credibility and strategic support.
A leading life sciences venture capital firm, Frazier Healthcare Partners provided key early-stage capital and guidance during the seed round. Their involvement was instrumental in launching Enlaza and supporting its early development efforts.
Avalon Ventures is a prominent VC focused on launching transformative biotech startups. As a co-lead in the seed round, Avalon Ventures was essential in providing seed funding and strategic mentorship during Enlaza’s formative years.
Pappas Capital invests in innovative life science companies and contributed to Enlaza Therapeutics funding rounds, offering sector expertise and supporting the company's growth trajectory.
Lightspeed Venture Partners participated in financing Enlaza’s growth, lending deep industry knowledge and a track record of fostering breakthrough life sciences companies.
Amgen Ventures supported Enlaza as a strategic corporate investor, recognizing the potential of its covalent protein therapeutics platform and providing industry-specific resources.
Regeneron Ventures invests in disruptive biotech advances and brought its insights and network to Enlaza’s investor base, reinforcing scientific and clinical development efforts.
Bregua Corporation joined as an investor, supporting Enlaza’s mission to pioneer next-generation protein drugs.
Samsara BioCapital added its expertise in biotechnology investment, helping drive the development and application of Enlaza’s War-Lock technology.
Alexandria Venture Investments, a leader in life science innovation capital, invested in Enlaza Therapeutics to bolster the company’s platform expansion and growth in the drug discovery field.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Enlaza Therapeutics funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.